(Q33360255)

26 July 2017

title

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura (English)

1 reference

Immune thrombocytopenic purpura

26 July 2017

1 reference

1 reference

1 reference

1 reference

Michael A Feuerstein

4

0 references

Sergio Amadori

object named as

Sergio Amadori

6

0 references

James Bruce Bussel

7

object named as

James B Bussel

1 reference

26 July 2017

2

Roberto Stasi

1 reference

26 July 2017

Nichola Cooper

1

1 reference

26 July 2017

Susanna Cunningham-Rundles

3

1 reference

26 July 2017

John P Leonard

5

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

125

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

232-239

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04889.X

10.1111/J.1365-2141.2004.04889.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference